« Return to News | CROs/Service Providers | Drug Sponsors

NCIC CTG to sponsor, conduct colorectal cancer study for Oncolytics

Friday, May 4, 2012 04:36 PM

Calgary, Alberta-based Oncolytics Biotech has chosen NCIC Clinical Trials Group at Queen's University in Kingston, Ontario, to sponsor and conduct a randomized phase II study of Reolysin in patients with advanced or metastatic colorectal cancer.

"We are pleased to be conducting a second randomized study with the NCIC CTG," said Brad Thompson, president and CEO of Oncolytics. "This study will build on both our early preclinical and clinical colorectal cancer work, as well as preclinical research combining Reolysin with Avastin. As a company, we intend to continue expanding our clinical program to  include randomized studies of frequently diagnosed cancers."

The study will be an open-label, randomized, non-blinded, phase II clinical study of Reolysin given in combination with Folfox-6 plus bevacizumab (Avastin) versus Folfox-6 plus bevacizumab alone. Approximately 50 response evaluable patients will be enrolled in each arm, after a six to nine patient safety run in.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 20

IRB consolidation trend continues, as private equity firm Audax buys majority stake in Chesapeake

Quintiles, Merck Serono ink exclusive partnership

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.